Breaking Down SG&A Expenses: Intra-Cellular Therapies, Inc. vs Supernus Pharmaceuticals, Inc.

A Comparative Analysis of SG&A Expenses: Intra-Cellular Therapies vs. Supernus Pharmaceuticals

In the competitive landscape of pharmaceuticals, understanding the financial dynamics of companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Intra-Cellular Therapies, Inc. and Supernus Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, Intra-Cellular Therapies saw a staggering increase in SG&A expenses, growing nearly 40 times from 2014 to 2023. In contrast, Supernus Pharmaceuticals experienced a more moderate growth, with expenses increasing by approximately 4.6 times during the same period.

By 2023, Intra-Cellular Therapies' SG&A expenses reached 409 million, surpassing Supernus Pharmaceuticals, which stood at 336 million. This shift highlights a strategic pivot in spending, possibly reflecting aggressive market expansion or increased operational costs. Such insights are invaluable for investors and stakeholders aiming to gauge the financial health and strategic direction of these pharmaceutical giants.